Ureteral Stent-related Pain and Mirabegron (SPAM) Trial
Klíčová slova
Abstraktní
Termíny
Poslední ověření: | 01/31/2017 |
První předloženo: | 02/16/2014 |
Odhadovaná registrace vložena: | 03/20/2014 |
První zveřejnění: | 03/25/2014 |
Poslední aktualizace byla odeslána: | 02/01/2017 |
Poslední aktualizace zveřejněna: | 02/02/2017 |
Aktuální datum zahájení studie: | 10/31/2014 |
Odhadované datum dokončení primární: | 07/31/2018 |
Odhadované datum dokončení studie: | 07/31/2018 |
Stav nebo nemoc
Intervence / léčba
Drug: Mirabegron
Drug: Tamsulosin
Drug: Tylenol #3
Fáze
Skupiny zbraní
Paže | Intervence / léčba |
---|---|
Active Comparator: Narcotic analegesic only Drug:
Tylenol #3 1 tablet every six hours as necessary | |
Active Comparator: Mirabegron and narcotic analgesia Drug :
Mirabegron 50 mg oral daily
Drug:
Tylenol #3 1 tablet every six hours as necessary | |
Active Comparator: Tamsulosin and narcotic analgesia Drug:
Tamsulosin 0.4mg oral daily Drug: Tylenol #3 1 tablet every six hours as necessary | |
Experimental: Mirabegron, Tamsulosin and narcotic Drug:
Mirabegron 50 mg oral daily
Drug:
Tamsulosin 0.4mg oral daily
Drug:
Tylenol #3 1 tablet every six hours as necessary |
Kritéria způsobilosti
Věky způsobilé ke studiu | 18 Years Na 18 Years |
Pohlaví způsobilá ke studiu | All |
Přijímá zdravé dobrovolníky | Ano |
Kritéria | Inclusion Criteria: - Age ≥18 years - First presentation for ureteroscopy for this particular stone - Planned insertion of double J ureteral stent - Planned ureteral stenting ≥5 days - Follow-up conducted at the Queen Elizabeth II Health Sciences Centre Exclusion Criteria: - Bilateral ureteral stents to be inserted - Stent already in situ prior to ureteroscopy - Patients with congenital renal abnormalities (ie: horseshoe kidney, ectopic kidney, etc) - Patients with urinary diversion - Patients with a history of interstitial cystitis/painful bladder syndrome, chronic prostatitis, or neurogenic bladder - Indwelling foley catheter - Active urinary tract infection - Patients currently taking antimuscarinics, mirabegron, or α-blockers - Patients with contraindications to receiving either mirabegron or tamsulosin (ie: urinary retention, end-stage renal disease, orthostatic hypotension, uncontrolled hypertension, known QT prolongation, severe aortic regurgitation), significant cognitive impairment, pregnancy, and active urinary tract infection - Planned upcoming elective cataract surgery - Suspected or confirmed ureteral perforation |
Výsledek
Primární výsledná opatření
1. Ureteral stent related pain and lower urinary tract symptoms (LUTS) as measured by the Ureteral Stent Symptom Questionnaire. [Measured twice, once at the time of surgery when stent is inserted and secondly at the time the stent is removed which will occur 5 to 10 days following surgery.]
Měření sekundárních výsledků
1. Quality of life impact of mirabegron for stent symptoms as measured with the Ureteral Stent Symptoms Questionnaire. [Measured twice, once at the time of surgery when stent is inserted and secondly at the time the stent is removed occuring 5 to 10 days later.]